ロード中...
Comparison of graft-versus-host disease-free, relapse-free survival according to a variety of graft sources: antithymocyte globulin and single cord blood provide favorable outcomes in some subgroups
Graft-versus-host disease-free relapse-free survival, which is defined as the absence of grade III–IV acute graft-versus-host disease, systemically treated chronic graft-versus-host disease, relapse, and death, is a novel, meaningful composite end point for clinical trials. To characterize risk fact...
保存先:
| 出版年: | Haematologica |
|---|---|
| 主要な著者: | , , , , , , , , , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Ferrata Storti Foundation
2016
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5479609/ https://ncbi.nlm.nih.gov/pubmed/27662017 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2016.149427 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|